Prexige 2007 Filing Target Assumes FDA Will Request Additional CV Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis assumes FDA will require two-year cardiovascular data for COX-2s following the withdrawal of Merck's Vioxx. Company expects to have "more detailed discussions" with the agency in early 2005 after FDA reviews 12-month data from the Prestige TARGET study.
You may also be interested in...
Novartis Will Resubmit COX-2 Inhibitor In The U.S. In 2007
Prexige is approved in EU and Canada for osteoarthritis symptoms, company announces.
Novartis Will Resubmit COX-2 Inhibitor In The U.S. In 2007
Prexige is approved in EU and Canada for osteoarthritis symptoms, company announces.
COX-2 Pipeline Drugs Will Need Additional Cardiovascular Data, FDA Says
COX-2 inhibitors in the R&D pipeline will need additional cardiovascular safety data prior to approval under FDA's risk management program for the drug class